

Hitting the Bullseye With Anti-BCMA Treatment – Clinical Brief #3

References

Tweet 3

Kumar S, D'Souza A, Shah N, et al. A phase 1 first-in-human study of Tnb-383B, a BCMA x CD3 bispecific T-Cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. *Blood*. 2021;138(Supplement 1):900-900. doi:10.1182/blood-2021-150757

Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. *N Engl J Med*. 2022;387(6):495-505. doi:10.1056/NEJMoa2203478

Sebag M, Raje NS, Bahlis NJ, et al. Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from Magnetism-1. *Blood*. 2021;138(Supplement 1):895-895. doi:10.1182/blood-2021-150519

Zonder JA, Richter J, Bumma N, et al. Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific monoclonal antibody, in a phase 1/2 first-in-human study in patients with relapsed/refractory multiple myeloma (RRMM). *Blood*. 2021;138(Supplement 1):160-160. doi:10.1182/blood-2021-144921

Tweet 6

BLNREP (belantamab mafodotin-blmf) [prescribing information]. GlaxoSmithKline. Approved 2020. Revised February 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761158s006lbl.pdf

CARVYKTI™ (ciltacabtagene autoleucel) [prescribing information]. Janssen Biotech, Inc. Approved 2022. Revised February 2022. <https://www.fda.gov/media/156560/download>

ABECMA® (idecabtagene vicleucel) [prescribing information]. Bristol-Myers Squibb. Approved 2021. Revised March 2021. <https://www.fda.gov/media/147055/download>

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Multiple Myeloma (v5.2022). Updated March 9, 2022. Accessed June 2, 2022. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

Tweet 7

Lonial S, Lee HC, Badros A, et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. *Cancer*. 2021;127(22):4198-4212. doi:10.1002/cncr.33809

Tweet 9

Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. *Lancet*. 2021;398(10297):314-324. doi:10.1016/S0140-6736(21)00933-8

Usmani SZ, Martin TG, Berdeja JG, et al. Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI. *J Clin Oncol*. 2022;40(16_suppl):8028-8028. doi:10.1200/JCO.2022.40.16_suppl.8028

Tweet 10

Anderson Jr LD, Shah N, Jagannath S, et al. OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa. *Clin Lymphoma Myeloma Leuk*. 2021;21:S17-S18. doi:10.1016/s2152-2650(21)02101-7

Glossary

ADC, antibody-drug conjugate
AE, adverse event
AST, aspartate aminotransferase
BCMA, B cell maturation antigen
BCVA, best-corrected visual acuity
Belamaf, belantamab mafodotin
CAR, chimeric antigen receptor
Cilta-cel, ciltacabtagene autoleucel
CRS, cytokine release syndrome
Ide-cel, idecabtagene vicleucel
IMiD, immunomodulatory drug
LOT, line of therapy
mAb, monoclonal antibody
mDOR, median duration of response
MM, multiple myeloma
mOS, median overall survival
mPFS, median progression-free survival
MRD, minimal residual disease
NE, not estimable
NR, not reached
ORR, overall response rate
OS, overall survival
PFS, progression-free survival
PI, proteasome inhibitor
PS, performance status
RRMM, relapsed/refractory multiple myeloma
T, T cell
VGPR, very good partial response
w/, with